NEW YORK (GenomeWeb News) – Rosetta Genomics reported after the close of the market on Friday that its revenues for full-year 2012 nearly doubled year over year.

Rosetta also announced a deal with Cantor Fitzgerald to serve as its agent in the sale of up to $5.9 million of its stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.